152 related articles for article (PubMed ID: 5535910)
1. Thyroid gland in Graves' disease: victim or culprit?
Chopra IJ; Solomon DH; Johnson DE; Chopra U
Metabolism; 1970 Oct; 19(10):760-72. PubMed ID: 5535910
[No Abstract] [Full Text] [Related]
2. Suppressibility of thyroid function despite high levels of long-acting thyroid stimulator.
Wong ET; Doe RP
Ann Intern Med; 1972 Jan; 76(1):77-84. PubMed ID: 4112158
[No Abstract] [Full Text] [Related]
3. Hypothyroidism with unusual features following propylthiouracil therapy of Graves' disease.
Pittman JG; Maloof F
Am J Med Sci; 1972 Dec; 264(6):499-505. PubMed ID: 4119609
[No Abstract] [Full Text] [Related]
4. Dissociation of serum LATS content and thyroid suppressibility during treatment of hyperthyroidism.
Chopra IJ; Solomon DH; Johnson DE; Chopra U; Fischer DA
J Clin Endocrinol Metab; 1970 Apr; 30(4):524-8. PubMed ID: 5435290
[No Abstract] [Full Text] [Related]
5. Inappropriate suppression of thyrotropin during medical treatment of Graves disease in childhood.
Sills IN; Horlick MN; Rapaport R
J Pediatr; 1992 Aug; 121(2):206-9. PubMed ID: 1640284
[TBL] [Abstract][Full Text] [Related]
6. Correlation between thyroid stimulators and 3,5,3'-triiodothyronine suppressibility in patients during treatment for hyperthyroidism with thionamide drugs: comparison of assays by thyroid-stimulating and thyrotropin-displacing activities.
Kuzuya N; Chiu SC; Ikeda H; Uchimura H; Ito K; Nagataki S
J Clin Endocrinol Metab; 1979 Apr; 48(4):706-11. PubMed ID: 581876
[No Abstract] [Full Text] [Related]
7. Abnormalities of hypothalamo-hypophyseal-thyroid axis in patients with Graves' ophthalmopathy.
Chopra IJ; Chopra U; Orgiazzi J
J Clin Endocrinol Metab; 1973 Dec; 37(6):955-67. PubMed ID: 4201831
[No Abstract] [Full Text] [Related]
8. Factors influencing the relationship between labelled triiodothyronine and thyroxine levels in the serum of patients with Graves' disease.
Földes J; Gyertyánfy G; Tako J; Bános C; Gesztesi E
Endokrinologie; 1973 Jan; 61(1):52-64. PubMed ID: 4739850
[No Abstract] [Full Text] [Related]
9. Thyroid suppressibility and long-acting thyroid stimulator in thyrotoxicosis.
Silverstein GE; Burke G
Arch Intern Med; 1970 Oct; 126(4):615-20. PubMed ID: 4097002
[No Abstract] [Full Text] [Related]
10. Pituitary-thyroid regulation in euthyroid patients with Graves' disease previously treated with antithyroid drugs.
Buerklin EM; Schimmel M; Utiger RD
J Clin Endocrinol Metab; 1976 Aug; 43(2):419-27. PubMed ID: 59733
[TBL] [Abstract][Full Text] [Related]
11. Suppressibility of thyroid function during treatment with antithyroid drugs in Grave's disease.
Wils JA; Kloppenborg PW
J Clin Endocrinol Metab; 1970 Mar; 30(3):406-7. PubMed ID: 4189571
[No Abstract] [Full Text] [Related]
12. The effect of radioablation of the thyroid gland in Graves' disease with high levels of long-acting thyroid stimulator (LATS).
Volpé R; Desbarats-Schonbaum ML; Schonbaum E; Row VV; Ezrin C
Am J Med; 1969 Feb; 46(2):217-26. PubMed ID: 5818477
[No Abstract] [Full Text] [Related]
13. The long-acting thyroid stimulatory: is it of importance in Graves' disease.
McKenzie JM; Zakarija M; D'Amour P; Joasoo A
N Z Med J; 1975 Jan; 81(531):18-21. PubMed ID: 165442
[No Abstract] [Full Text] [Related]
14. Thyroidal effects of injections of Graves' disease thyroid microsomes in rhesus monkeys.
Furth ED; Dentinger M
Endocrinology; 1971 Jul; 89(1):310-5. PubMed ID: 4103749
[No Abstract] [Full Text] [Related]
15. Thyrotrophin response to thyrotrophin-releasing hormone in ophthalmic Graves' disease: correlation with other aspects of thyroid function, thyroid suppressibility and activity of eye signs.
Ormston BJ; Alexander L; Evered DC; Clark F; Bird T; Appleton D; Hall R
Clin Endocrinol (Oxf); 1973 Oct; 2(4):369-76. PubMed ID: 4128973
[No Abstract] [Full Text] [Related]
16. Thyroid suppression test and outcome of hyperthyroidism treated with antithyroid drugs and triiodothyronine.
Yamamoto M; Igarashi T; Kimura S; Tsukamoto S; Togawa K; Ogata E
J Clin Endocrinol Metab; 1979 Jan; 48(1):72-7. PubMed ID: 581766
[No Abstract] [Full Text] [Related]
17. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
Tsai WC; Pei D; Wang TF; Wu DA; Li JC; Wei CL; Lee CH; Chen SP; Kuo SW
Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
[TBL] [Abstract][Full Text] [Related]
18. Current concepts in management of thyroid disease.
DeGroot LJ
Med Clin North Am; 1970 Jan; 54(1):117-30. PubMed ID: 4189143
[No Abstract] [Full Text] [Related]
19. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
20. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease.
Roti E; Minelli R; Gardini E; Bianconi L; Salvi M; Gavaruzzi G; Ugolotti G; Braverman LE
J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
